Den Europæiske Union - engelsk - EMA (European Medicines Agency)

pfizer europe ma eeig - pemetrexed ditromethamine - carcinoma, non-small-cell lung; mesothelioma - folic acid analogues, antimetabolites - malignant pleural mesotheliomapemetrexed hospira uk limited in combination with cisplatin is indicated for the treatment of chemotherapy naïve patients with unresectable malignant pleural mesothelioma.non-small cell lung cancerpemetrexed hospira uk limited in combination with cisplatin is indicated for the first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology (see smpc section 5.1).pemetrexed hospira uk limited is indicated as monotherapy for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology in patients whose disease has not progressed immediately following platinum-based chemotherapy (see smpc section 5.1).pemetrexed hospira uk limited is indicated as monotherapy for the second-line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology (see smpc section 5.1).

Australien - engelsk - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - cisatracurium besilate -

Australien - engelsk - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - cisatracurium besilate -

Sydafrika - engelsk - South African Health Products Regulatory Authority (SAHPRA)

pfizer laboratories (pty) ltd - tablet - see ingredients - each tablet contains misoprostol 200 ug

Australien - engelsk - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - ropivacaine hydrochloride -

Australien - engelsk - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - ropivacaine hydrochloride -

USA - engelsk - NLM (National Library of Medicine)

pfizer laboratories div pfizer inc - varenicline tartrate (unii: 82269asb48) (varenicline - unii:w6hs99o8zo) - varenicline 0.5 mg - chantix is indicated for use as an aid to smoking cessation treatment. chantix is contraindicated in patients with a known history of serious hypersensitivity reactions or skin reactions to chantix. risk summary available data have not suggested an increased risk for major birth defects following exposure to varenicline in pregnancy, compared with women who smoke [see data]. smoking during pregnancy is associated with maternal, fetal, and neonatal risks (see clinical considerations) . in animal studies, varenicline did not result in major malformations but caused decreased fetal weights in rabbits when dosed during organogenesis at exposures equivalent to 50 times the exposure at the maximum recommended human dose (mrhd). additionally, administration of varenicline to pregnant rats during organogenesis through lactation produced developmental toxicity in offspring at maternal exposures equivalent to 36 times human exposure at the mrhd [see data] . the estimated background risk of oral clefts is increased by

USA - engelsk - NLM (National Library of Medicine)

pfizer laboratories div pfizer inc - tofacitinib citrate (unii: o1ff4div0d) (tofacitinib - unii:87la6fu830) - tofacitinib 5 mg - xeljanz/xeljanz xr is indicated for the treatment of adult patients with moderately to severely active rheumatoid arthritis (ra) who have had an inadequate response or intolerance to one or more tnf blockers. xeljanz/xeljanz xr is indicated for the treatment of adult patients with active psoriatic arthritis (psa) who have had an inadequate response or intolerance to one or more tnf blockers. xeljanz/xeljanz xr is indicated for the treatment of adult patients with active ankylosing spondylitis (as) who have had an inadequate response or intolerance to one or more tnf blockers. xeljanz/xeljanz xr is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis (uc), who have an inadequate response or intolerance to one or more tnf blockers. xeljanz/xeljanz oral solution is indicated for the treatment of active polyarticular course juvenile idiopathic arthritis (pcjia) in patients 2 years of age and older who have had an inadequate response or intolerance to one or more tnf

Australien - engelsk - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - tobramycin, quantity: 80 mg - injection, solution - excipient ingredients: sodium hydroxide; sodium metabisulfite; phenol; water for injections; sulfuric acid; disodium edetate - for the treatment of serious infections of the following type where they are caused by susceptible organisms: skin and skin structure infections including burns, bone infections; gastrointestinal infections including peritonitis; central nervous system infections including meningitis, septicaemia and neonatal sepsis; lower respiratory tract infections including pneumonia, bronchopneumonia, and acute bronchitis; complicated and recurrent urinary tract infections such as pyelonephritis and cystitis.,aminoglycosides, including tobramycin, should not be used in uncomplicated initial episodes of urinary tract infection unless the causative organisms are not susceptible to other less toxic antibiotics.,tobramycin can be used in serious staphylococcal infections for which penicillin or other less toxic drugs are contraindicated and where susceptibility testing and clinical judgement indicate its use. if susceptibility tests show a resistance to tobramycin in the causative organisms other appropriate therapy should be instituted.,note that bacterial cultures should bo obtained before and during treatment to isolate and identify etiologic organisms and to test their susceptibility to tobramycin. if the organisms are resistant, other appropriate therapy should be instituted. in patients in whom gram-negative septicaemia, neonatal sepsis or meningitis is suspected, including those in whom concurrent therapy with a penicillin or cefalosporin and an aminoglycoside may be indicated, tobramycin therapy may be initiated before results of susceptibility studies are obtained. the decision to continue tobramycin therapy should be based upon the results of susceptibility studies, the severity of infection and the important additional concepts discussed in the product information leaflet.

Australien - engelsk - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - tobramycin, quantity: 80 mg - injection, solution - excipient ingredients: water for injections; disodium edetate; sodium hydroxide; sulfuric acid - for the treatment of serious infections of the following type where they are caused by susceptible organisms: skin and skin structure infections including burns, bone infections; gastrointestinal infections including peritonitis; central nervous system infections including meningitis, septicaemia and neonatal sepsis; lower respiratory tract infections including pneumonia, bronchopneumonia, and acute bronchitis; complicated and recurrent urinary tract infections such as pyelonephritis and cystitis.,aminoglycosides, including tobramycin, should not be used in uncomplicated initial episodes of urinary tract infection unless the causative organisms are not susceptible to other less toxic antibiotics.,tobramycin can be used in serious staphylococcal infections for which penicillin or other less toxic drugs are contraindicated and where susceptibility testing and clinical judgement indicate its use. if susceptibility tests show a resistance to tobramycin in the causative organisms other appropriate therapy should